International Niemann–Pick Disease Alliance
Sometimes in such a big organisation as the INPDA, our various member groups can be overshadowed, but we want to show just how important each and every member group is in making the INPDA work. In the INPDA Spotlight this...
Join us on Wednesday June 30th at 7pm BST to hear an update direct from Cyclo Therapeutics regarding their Phase 3 Clinical trial of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C: The INPDA is pleased to...
Orphazyme A/S Company announcement No. 16/2021 Inside information Company Registration No. 32266355 Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today...
Company plans to produce up to an additional two years’ supply of drug for eligible patients Agreement is subject to approval by U.S. Bankruptcy Court in Delaware Mallinckrodt Pharmaceuticals has reached an agreement to divest and transfer the Investigational...
Sometimes in such a big organisation as the INPDA, our various member groups can be overshadowed, but we want to show just how important each and every member group is in making the INPDA work. In the INPDA Spotlight this...